The estimated Net Worth of Liam Ratcliffe is at least $76.5 million dollars as of 14 December 2021. Liam Ratcliffe owns over 355,705 units of Arvinas Inc stock worth over $4,621,725 and over the last 12 years he sold ARVN stock worth over $71,636,591. In addition, he makes $215,236 as Independent Director at Arvinas Inc.
Liam has made over 15 trades of the Arvinas Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 355,705 units of ARVN stock worth $23,832,235 on 14 December 2021.
The largest trade he's ever made was selling 1,673,172 units of Arvinas Inc stock on 12 September 2013 worth over $10,172,886. On average, Liam trades about 213,801 units every 92 days since 2012. As of 14 December 2021 he still owns at least 185,686 units of Arvinas Inc stock.
You can see the complete history of Liam Ratcliffe stock trades at the bottom of the page.
Dr. Liam Ratcliffe M.D., Ph.D. serves as Independent Director of the Company. Dr. Ratcliffe has been Head of Access Biotechnology, a privately held group, since April 2019. From September 2008 to March 2019, Dr. Ratcliffe was a Managing Director and Member of New Leaf Venture Partners LLC, a venture capital firm. Previously, Dr. Ratcliffe was Senior Vice President and Development Head for Neuroscience, as well as Worldwide Head of Clinical Research and Development at Pfizer, a biopharmaceutical company. Dr. Ratcliffe currently serves on the board of directors of the publicly-traded company Passage Bio, Inc. and previously served on the board of directors of the publicly-traded companies Aptinyx, Inc., Array BioPharma Inc., Deciphera Pharmaceuticals, Inc., Edge Therapeutics, Inc. and Unum Therapeutics, Inc. Dr. Ratcliffe holds a Ph.D. in immunology and an M.D. from the University of Cape Town and an M.B.A. from the University of Michigan. Ratcliffe is qualified to serve on our board due to his extensive experience in the venture capital industry, his medical and scientific background and training, and his service on the boards of directors of public and private biopharmaceutical companies.
As the Independent Director of Arvinas Inc, the total compensation of Liam Ratcliffe at Arvinas Inc is $215,236. There are 13 executives at Arvinas Inc getting paid more, with John Houston having the highest compensation of $5,485,840.
Liam Ratcliffe is 56, he's been the Independent Director of Arvinas Inc since 2015. There are 10 older and 8 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
Liam's mailing address filed with the SEC is C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN, CT, 06511.
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe et Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: